ANNOUNCEMENT

MedCity CONVERGE July 9-10 in Philly gathers payers, providers, medtech, pharma, digital health, policymakers & more.

Thermo Fisher adds supply chain link with $175M Doe & Ingalls acquisition

May 2, 2012 10:00 am by | 0 Comments

chain, link, supply chain

Thermo Fisher Scientific (NYSE:TMO) is boosting its supply chain capabilities with its $175 million purchase of chemicals supplier Doe & Ingalls.

Durham, North Carolina-based Doe & Ingalls provides specialty chemicals for companies in the life sciences and microelectronics industry. Doe & Ingalls’ 2011 revenue was approximately $110 million.

The acquisition by Waltham, Massachusetts-based Thermo Fisher is a homecoming of sorts for Doe & Ingalls. One of the firm’s legacy businesses — also called Doe & Ingalls — was founded in Massachusetts in 1921 as a chemicals distributor. Doe & Ingalls North Carolina was founded in 1986 as an independent company serving Research Triangle Park. That business expanded to sites in Maryland, Florida and California — all locations with concentrations of life science and electronics companies.

Advertisement

Private equity firms Pouschine Cook Capital and Anchor Capital purchased Doe & Ingalls North Carolina in 2005. In 2010, Doe & Ingalls Management, parent of Doe & Ingalls North Carolina, acquired the Massachusets Doe & Ingalls. The combined company went by the name Doe & Ingalls.

Doe & Ingalls now becomes part of Thermo Fisher’s customer channels business within its Laboratory Products and Services Segment. This business line provides virtually everything needed in a laboratory for customers that include pharmaceutical companies, academic researchers, government sites and industrial facilities. Of Thermo Fisher’s three business segments, Laboratory Products and Services is the largest, generating $5.9 billion in 2011 revenue.

“Doe & Ingalls will strengthen our value proposition by adding products and services that address the production market within our extensive customer base, which we have historically served primarily from a research perspective,” Thermo Fisher CEO Marc Casper said in a statement.

[Photo from stock.xchng user raZna]

Copyright 2013 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

By Frank Vinluan

Frank Vinluan is the North Carolina Bureau Chief for MedCity News.
More posts by Author

0 comments

Stay Up To Date

Recent Comments

Research Center

Jobs Board

Next Story
Morning Read: Preparing for the 2013 patent law, sharing ACO refunds fairly
Close